230 likes | 367 Views
Structural Studies of St AhpC2 and Mp GlpO. By: Callia K. Palioca Mentor: Dr. P. Andrew Karplus Department of Biochemistry & Biophysics, OSU HHMI Summer Program 2010. Proteins are IMPORTANT. Enzymes are vital in all of life’s functions Most drugs interact with proteins. Myosin. Actin.
E N D
Structural Studies of StAhpC2 and MpGlpO By: Callia K. Palioca Mentor: Dr. P. Andrew Karplus Department of Biochemistry & Biophysics, OSU HHMI Summer Program 2010
Proteins are IMPORTANT • Enzymes are vital in all of life’s functions • Most drugs interact with proteins Myosin Actin
Protein Structure Matters • Function flows from structure • Structure-based drug design HIV protease drug complex
X-RayCrystallographyMethods • Grow Crystal • Diffraction & Data Processing • Solve the Phase Problem • Electron Density Map • Refinement of Structure • Goal: Obtain single, high-quality diffracting crystals and use the data to solve the structure
Food Poisoning Macrophage attacking bacteria
StAhpC2 and thePeroxiredoxins • Catalytic cycle of this family of proteins • Function: uses cysteine residues to breakdown peroxides
How Motifs Relate to Sensitivity • Correlation between YF and a helical structure • Leads to sensitive enzymes Sensitive Robust
AhpC2 C50S • YL vs. YF • Seen in significant human pathogens that cause African sleeping sickness, ulcers, malaria, and Beaver Fever
Hypothesis • StAhpC2 is a representative of the proteins in deadly human pathogens • Structure gives insights into pathogen survival in humans and forms basis for drug design • YF motif significance can also be studied
Crystals! • Pure protein from Dr. Leslie Poole’s lab, WFU • Optimizing conditions • (NH4)2HPO4 • pH
Crystals! Predictions do not line up Stalled progress
The Mycoplasma Diseases • Mycoplasmapneumoniae • Walking pneumonia • Mycoplasmamycoides • Contagious bovine pleuropnemonia
What is known • Structure of GlpO • No substrates able to be bound • DHAP, tartaric acid, 2-phosphoglycerate, menadione, G3P, phosphoenolpyruvate
Hypothesis • Drug target • Substrates, products and inhibitors in GlpO • Insight into Mycoplasmaand other organisms cause disease • Basis for structure-based drug design
Crystallization • Pure protein from Dr. Al Claiborne’s lab, WFU • NaCl and neutral-basic pH buffer
Diffraction and Data Processing • Resolution: enough to define atomic structure (3.0 Å)
Molecular Replacement • The Phase Problem • Structure of related protein (3DME) Height
A Good Solution • Differences between model and map
Structure Refinement • Process of manually changing sequence • Avoiding model bias
Future Work • Continue refinement of structure • Soaking of substrates • Optimization of cryo-protectant • 15% glycerol 0% glycerol 10% glycerol 15% glycerol
Acknowledgements • Dr. P. Andrew Karplus • The rest of the Karplus lab • Dr. Andrea Hall, Camden Driggers, Ian Winter • HHMI, Cripps • URISC • Our collaborators at Wake Forest University • Dr. Leslie Poole • Dr. Al Claiborne • Dr. Kevin Ahern